IOMX-0675

N/A

Report date: 2025/04/27 14:53:32

Base Information

Drug NameIOMX-0675

Drug Alias NameIOMX-0675

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionLeukocyte immunoglobulin-like receptor B1 inhibitorsLeukocyte immunoglobulin-like receptor subfamily B member 2 inhibitors

TargetsLeukocyte immunoglobulin-like receptor B1Leukocyte immunoglobulin-like receptor subfamily B member 2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesIOmx Therapeutics AG

China Registration ClassN/A

Develop Information

Active CompaniesIOmx Therapeutics AG

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A